Survival outcomes in hormone receptor-negative breast cancer among BRCA carriers versus noncarriers in western Sweden
DOI:
https://doi.org/10.2340/1651-226X.2025.43109Keywords:
HR-negative, ER-negative, TNBC, Genetic testing, hereditary breast cancerAbstract
Background and purpose: BRCA-related hormone receptor (HR)-negative breast cancers (BC) are reported to have aggressive tumor biology but also exhibit chemosensitivity. However, the impact of BRCA1/2 pathogenetic variants (PV) on BC outcomes remains unclear. This study compares survival outcomes for HR-negative BC between BRCA carriers and noncarriers.
Patients/material and methods: From 489 female BRCA-carriers prospectively registered in western Sweden (1996–2017), those with primary HR-negative BC who underwent breast surgery until 2019 were included in the BRCA cohort. For each BRCA-carrier, three BRCA-noncarriers with HR-negative BC were matched based on age, time of diagnosis, and follow-up duration. Overall survival (OS) was analyzed using Kaplan‑Meier estimates and Cox proportional hazard ratios after adjustment for stage, chemotherapy, and surgical technique. A sensitivity analysis was performed to investigate the effect of HER2 status on HR-negative BC diagnosed after 2007.
Results: Among the 106 BRCA carriers, 101 (95%) had a BRCA1 and 5 (5%) a BRCA2 PV. Most of the BRCA-carriers (89/106, 84%) were diagnosed with BC prior to genetic screening. Surgical techniques were similar between BRCA-carriers (n = 106) and noncarriers (n = 318). Chemotherapy was more common among BRCA-carriers (87% vs. 72%, p < 0.001). No significant difference in OS was found between BRCA-carriers and noncarriers among patients with HR-negative BC (adjusted HR: 0.81 [95% confidence interval [CI]: 0.43–1.53], p = 0.51) or considering HER2 status (adjusted HR 0.95 [95% CI: 0.43–2.07], p = 0.89).
Interpretation: This study suggests that BRCA1/2 pathogenic variants do not independently impact survival outcomes in HR-negative BC. However, a moderate association between BRCA status and OS cannot be ruled out.
Downloads
References
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34:927–35.
https://doi.org/10.1200/JCO.2015.62.3504 DOI: https://doi.org/10.1200/JCO.2015.62.3504
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5): dju055.
https://doi.org/10.1093/jnci/dju055 DOI: https://doi.org/10.1093/jnci/dju055
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
https://doi.org/10.1158/1078-0432.CCR-06-3045 DOI: https://doi.org/10.1158/1078-0432.CCR-06-3045
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16. DOI: https://doi.org/10.1001/jama.2017.7112
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
https://doi.org/10.1056/NEJMra1001389 DOI: https://doi.org/10.1056/NEJMra1001389
Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, et al. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. BMC Cancer. 2023;23:738.
https://doi.org/10.1186/s12885-023-11229-y DOI: https://doi.org/10.1186/s12885-023-11229-y
NCCN. NCCN guidelines: National Comprehensive Cancer Network. 2025 [cited 2025 Mar 31]. Available from: https://www.nccn.org/
Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–95.
https://doi.org/10.1002/cncr.26576 DOI: https://doi.org/10.1002/cncr.26576
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.
https://doi.org/10.1158/1078-0432.CCR-10-2560 DOI: https://doi.org/10.1158/1078-0432.CCR-10-2560
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282–8.
https://doi.org/10.1200/JCO.2008.16.6231 DOI: https://doi.org/10.1200/JCO.2008.16.6231
Jóhannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362–71.
https://doi.org/10.1016/S0959-8049(97)89007-7 DOI: https://doi.org/10.1016/S0959-8049(97)89007-7
Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.
https://doi.org/10.1001/jamaoncol.2017.1007 DOI: https://doi.org/10.1001/jamaoncol.2017.1007
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
https://doi.org/10.1126/science.7545954 DOI: https://doi.org/10.1126/science.7545954
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.
https://doi.org/10.1038/378789a0 DOI: https://doi.org/10.1038/378789a0
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–7.
https://doi.org/10.1038/ng0396-333 DOI: https://doi.org/10.1038/ng0396-333
Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer. 2001;37:1904–9.
https://doi.org/10.1016/S0959-8049(01)00223-4 DOI: https://doi.org/10.1016/S0959-8049(01)00223-4
Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P. Increased overall mortality even after risk reducing surgery for BRCA-positive women in western Sweden. Genes (Basel). 2019;10(12):1046.
https://doi.org/10.3390/genes10121046 DOI: https://doi.org/10.3390/genes10121046
van den Broek AJ, Schmidt MK, van ‘t Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis. PLoS One. 2015;10:e0120189.
https://doi.org/10.1371/journal.pone.0120189 DOI: https://doi.org/10.1371/journal.pone.0120189
SCB. Statistics Sweden 2025. [cited 2025 Mar 31]. Available from: https://www.scb.se/en/
Wikipedia. Västra sjukvårdsregionen. Wikipedia; 2025 [cited 2025
Mar 31]. Available from: https://sv.wikipedia.org/wiki/V%C3%A4stra_sjukv%C3%A5rdsregionen.
STROBE. STROBE statement – checklist of items that should be included in reports of observational studies. STROBE; 2025 [cited 2025 Mar 10]. Available from: https://www.strobe-statement.org/checklists/
RCC. Nationellt vårdprogram bröstcancer: regionala cancercentrum i samverkan. 2025 [cited 2025 Mar 31]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/
NKBC. National Quality Register for Breast Cancer (NKBC). NKBC; 2025. [cited 2025 Mar 31] Available from: https://statistik.incanet.se/brostcancer/
Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229–35.
https://doi.org/10.1016/j.clbc.2017.12.014 DOI: https://doi.org/10.1016/j.clbc.2017.12.014
Wang Y, Dackus GMHE, Rosenberg EH, Cornelissen S, de Boo LW, Broeks A, et al. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status. BMC Med. 2024;22:9.
https://doi.org/10.1186/s12916-023-03233-7 DOI: https://doi.org/10.1186/s12916-023-03233-7
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–80.
https://doi.org/10.1016/S1470-2045(17)30891-4 DOI: https://doi.org/10.1016/S1470-2045(17)30891-4
Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018;10:5329–38.
https://doi.org/10.2147/CMAR.S176763 DOI: https://doi.org/10.2147/CMAR.S176763
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.
https://doi.org/10.1200/JCO.2020.38.15_suppl.1000 DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.1000
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.
https://doi.org/10.1056/NEJMoa1910549 DOI: https://doi.org/10.1056/NEJMoa1910549
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.
https://doi.org/10.1016/j.annonc.2020.08.2243 DOI: https://doi.org/10.1016/j.annonc.2020.08.2243
Geyer CE, Jr., Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250–68. DOI: https://doi.org/10.1016/j.annonc.2022.09.159
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
https://doi.org/10.1056/NEJMoa1706450 DOI: https://doi.org/10.1056/NEJMoa1706450
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526–35.
https://doi.org/10.1016/j.annonc.2020.08.2098 DOI: https://doi.org/10.1016/j.annonc.2020.08.2098
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.
https://doi.org/10.1056/NEJMoa2028485 DOI: https://doi.org/10.1056/NEJMoa2028485
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Anna-Karin Tzikas, Erik Holmberg, Toshima Z. Parris, Anikó Kovács, Lovisa Lovmar, Per Karlsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
